NextCure Inc., a clinical-stage biopharmaceutical company, has entered a strategic partnership with Simcere Zaiming, an oncology-focused biopharmaceutical company, to develop SIM0505, a novel antibody-drug conjugate $(ADC)$ targeting CDH6 for the treatment of solid tumors. Under the agreement, NextCure gains global rights to SIM0505, excluding greater China, where Simcere Zaiming will retain rights. SIM0505 is currently undergoing Phase 1 clinical testing in China, with plans for U.S. clinical trials to begin in the third quarter of 2025. This collaboration also grants NextCure access to Simcere Zaiming's proprietary linker and payload for use in an ADC directed to a novel target by NextCure, while Simcere Zaiming maintains rights in greater China. Simcere Zaiming is eligible for payments up to $745 million, along with tiered royalties on net sales outside of greater China. This partnership aims to accelerate drug development and provide new cancer therapies to patients globally.